Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation CCVVC 2015

Have SYNTAX and FREEDOM Trial Results Changed the Interventional Practice in the USA?

Presenter: Spencer B. King

June 19, 2015

Presentation TCT 2013

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

Presenter: Yuejin Yang

October 29, 2013

Presentation TCT 2013

Yes! With Current DES and Pharmacotherapy, SYNTAX Is Already Obsolete and the Majority of Patients with MVD Can Be Managed with PCI

Presenter: Dean Kereiakes

October 28, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

Should the Presence of Diabetes Move Treatment Toward CABG Rather Than PCI? Historical Observations and Syntax Score II

Presenter: Patrick Serruys

October 28, 2013

Presentation TCT 2013

Per-Lesion Inter-observer Variability and Impact on Syntax Score

Presenter: Gerardo Nau, Pablo Lamelas, Mariano Albertal, Jorge Belardi, Lucio Padilla, Sebastian Peralta, Fabricio Torrent, Fernando Cura

January 31, 2013

Presentation TCT 2012

SYNTAX SCORE II: An Improved Risk Score Based on Clinical and Angiographic Variables

Presenter: Vasim Farooq

October 25, 2012

Presentation TCT 2012

TCT-43. Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease

Presenter: A. Pieter Kappetein

October 23, 2012

Presentation TCT 2012

TAXUS: Final Five-Year SYNTAX Results (Entire Study Population)

Presenter: Patrick Serruys

October 22, 2012

Presentation TCT 2012

Multivessel Disease 1: Final Five-Year SYNTAX Results in the MVD Cohort

Presenter: A. Pieter Kappetein

October 22, 2012

Advertisement

Have SYNTAX and FREEDOM Trial Results Changed the Interventional Practice in the USA?

TCT-21. Prognosis of Clinical Outcomes in Chinese Patients Receiving XIENCE V Everolimus-Eluting Stent with Baseline and Residual Syntax Score: One-Year Results from the...

Yes! With Current DES and Pharmacotherapy, SYNTAX Is Already Obsolete and the Majority of Patients with MVD Can Be Managed with PCI

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Should the Presence of Diabetes Move Treatment Toward CABG Rather Than PCI? Historical Observations and Syntax Score II

Per-Lesion Inter-observer Variability and Impact on Syntax Score

SYNTAX SCORE II: An Improved Risk Score Based on Clinical and Angiographic Variables

TCT-43. Final Five-year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients with Three-vessel Disease

TAXUS: Final Five-Year SYNTAX Results (Entire Study Population)

Multivessel Disease 1: Final Five-Year SYNTAX Results in the MVD Cohort

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content